Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug dials down the energy within cells

10.07.2006
A drug effective at treating animal models of human autoimmune disorders and other diseases works by dialing down the activity of a key enzyme involved in energy production, University of Michigan researchers have found.

"Many drugs block the function of enzymes, essentially turning them off ," said Gary Glick, who is the Werner E. Bachmann Collegiate Professor of Chemistry at U-M. "Our compound works more like a volume control, so we’re able to dial enzyme activity down to a level that maintains normal function while simultaneously allowing for initiation of a process that selectively kills or disables disease-causing cells."

Glick and collaborators published their findings in the June 16 issue of ACS Chemical Biology.

The drug, discovered by Glick and coworkers and called benzodiazepine-423 (Bz-423), is a chemical cousin of anti-anxiety medications such as Valium and Xanax. In previous work, Glick’s group showed that Bz-423 reduces effects of arthritis and the autoimmune disease lupus in mice and may be useful in treating psoriasis. Unlike conventional drugs for these conditions, which can’t discriminate between healthy and disease-causing cells, Bz-423 is highly selective, homing in on disease-causing cells.

In an attempt to better exploit its therapeutic properties, the researchers have been studying the details of Bz-423’s activity. They learned that the compound targets an enzyme inside mitochondria, the energy factories of cells. The specific enzyme, F1F0-ATPase, is responsible for producing most of the cell’s ATP. That’s a critical role because ATP, often referred to as the cell’s energy currency, is the molecule that captures chemical energy from food and transfers it to energy-demanding processes, such as muscle contraction and the transmission of nerve signals.

"People had proposed in the past that if you could inhibit this enzyme, there might be therapeutic potential. But the problem is, if you inhibit the enzyme in the way most powerful drugs do, turning it off, you deplete the cell of ATP, and that’s fatal," Glick said. "Our new work reveals the mechanism by which Bz-423 inhibits the enzyme while still allowing it to function. This is important because it suggests principles that may be useful for targeting other bioenergetic pathways. Now we have some rules that we can apply to be able to modulate the mitochondria in new ways that could be therapeutic."

Ultimately, the findings may have applications not only for lupus, arthritis and psoriasis, but also for other conditions, Glick believes. "There are other diseases – certain cancers and a number of other immune diseases – where we think the way the cells make and utilize energy is fundamental to the disease process. Combining that knowledge with our new knowledge of how to regulate the energy of the cell could open up new avenues for treating disease and monitoring the effectiveness of treatment."

Glick collaborated on the research with Carol Fierke, who is the Jerome and Isabella Karle Collegiate Professor of Chemistry; Anthony Opipari, Jr., associate professor of obstetrics and gynecology; graduate student Kathryn Johnson and postdoctoral fellow Joanne Cleary. The researchers received funding from the National Institutes of Health.

Nancy Ross-Flanigan | EurekAlert!
Further information:
http://www.umich.edu

More articles from Life Sciences:

nachricht Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)

nachricht CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>